Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2018

03.01.2018 | Clinical trial

Observation versus excision of lobular neoplasia on core needle biopsy of the breast

verfasst von: Hank Schmidt, Brittany Arditi, Margaux Wooster, Christina Weltz, Laurie Margolies, Ira Bleiweiss, Elisa Port, Shabnam Jaffer

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Controversy surrounds management of lobular neoplasia (LN), [atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)], diagnosed on core needle biopsy (CNB). Retrospective series of pure ALH and LCIS reported “upgrade” rate to DCIS or invasive cancer in 0–40%. Few reports document radiologic/pathologic correlation to exclude cases of discordance that are the likely source of most upgrades, and there is minimal data on outcomes with follow-up imaging and clinical surveillance.

Methods

Cases of LN alone on CNB (2001–2014) were reviewed. CNB yielding LN with other pathologic findings for which surgery was indicated were excluded. All patients had either surgical excision or clinical follow-up with breast imaging. All cases included were subject to radiologic–pathologic correlation after biopsy.

Results

178 cases were identified out of 62213 (0.3%). 115 (65%) patients underwent surgery, and 54 (30%) patients had surveillance for > 12 months (mean = 55 months). Of the patients who underwent surgical excision, 13/115 (11%) were malignant. Eight of these 13 found malignancy at excision when CNB results were considered discordant (5 DCIS, and 3 invasive lobular carcinoma), with the remainder, 5/115 (4%), having a true pathologic upgrade: 3 DCIS, and 2 microinvasive lobular carcinoma. Among 54 patients not having excision, 12/54 (22%) underwent subsequent CNB with only 1 carcinoma found at the initial biopsy site.

Conclusions

Surgical excision of LN yields a low upgrade rate when careful consideration is given to radiologic/pathologic correlation to exclude cases of discordance. Observation with interval breast imaging is a reasonable alternative for most cases.
Literatur
1.
Zurück zum Zitat Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM (2013) Trends in incidence and management of lobular carcinoma in situ: a population based analysis. Ann Surg Oncol 20(10):3240–3246CrossRefPubMed Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM (2013) Trends in incidence and management of lobular carcinoma in situ: a population based analysis. Ann Surg Oncol 20(10):3240–3246CrossRefPubMed
2.
Zurück zum Zitat Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve year observations concerning lobular carcinoma in situ. Cancer 100:238–244CrossRefPubMed Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve year observations concerning lobular carcinoma in situ. Cancer 100:238–244CrossRefPubMed
3.
Zurück zum Zitat McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, Dupont WD, Page DL (2006) Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer 107(6):1227–1233CrossRefPubMed McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, Dupont WD, Page DL (2006) Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy. Cancer 107(6):1227–1233CrossRefPubMed
4.
Zurück zum Zitat Page DL, Kidd TE Jr, Dupont WE, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22(12):1232–1239CrossRefPubMed Page DL, Kidd TE Jr, Dupont WE, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22(12):1232–1239CrossRefPubMed
5.
Zurück zum Zitat Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long term followup study. Cancer 55(11):2698–2708CrossRefPubMed Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long term followup study. Cancer 55(11):2698–2708CrossRefPubMed
6.
Zurück zum Zitat Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C (2004) Lobular carcinoma in situ or atypical lobular hyperplasia at core needle biopsy: is excisional biopsy necessary? Radiology 231:813–819CrossRefPubMed Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C (2004) Lobular carcinoma in situ or atypical lobular hyperplasia at core needle biopsy: is excisional biopsy necessary? Radiology 231:813–819CrossRefPubMed
7.
Zurück zum Zitat Houssami N, Ciatto S, Bilous M, Vezzosi V, Bianchi S (2007) Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). Br J Cancer 96:1253–1257CrossRefPubMedPubMedCentral Houssami N, Ciatto S, Bilous M, Vezzosi V, Bianchi S (2007) Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). Br J Cancer 96:1253–1257CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Hwang H, Barke L, Mendelson EB, Susnik B (2008) Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol 21:1208–1216CrossRefPubMed Hwang H, Barke L, Mendelson EB, Susnik B (2008) Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary. Mod Pathol 21:1208–1216CrossRefPubMed
9.
Zurück zum Zitat Ibrahim N, Bessissow A, Lalonde L, Mesurolle B, Trop I, Lisbona A, El-Khoury M (2012) Any difference between lobular carcinoma in situ and atypical lobular hyperplasia? AJR 198:288–291CrossRefPubMed Ibrahim N, Bessissow A, Lalonde L, Mesurolle B, Trop I, Lisbona A, El-Khoury M (2012) Any difference between lobular carcinoma in situ and atypical lobular hyperplasia? AJR 198:288–291CrossRefPubMed
10.
Zurück zum Zitat Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ (2007) The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol 31:717–723CrossRefPubMed Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ (2007) The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol 31:717–723CrossRefPubMed
11.
Zurück zum Zitat Brem RF, Lechner MC, Jackman RJ, Rapelyea JA, Evans WP, Philpotts LE, Hargreaves J, Wasden S (2008) Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR 190:637–641CrossRefPubMed Brem RF, Lechner MC, Jackman RJ, Rapelyea JA, Evans WP, Philpotts LE, Hargreaves J, Wasden S (2008) Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR 190:637–641CrossRefPubMed
12.
Zurück zum Zitat Lavoue V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Leveque J (2007) Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow up surgical excision. Breast 16:533–539CrossRefPubMed Lavoue V, Graesslin O, Classe JM, Fondrinier E, Angibeau H, Leveque J (2007) Management of lobular neoplasia diagnosed by core needle biopsy: study of 52 biopsies with follow up surgical excision. Breast 16:533–539CrossRefPubMed
13.
Zurück zum Zitat Londero V, Zuiani C, Linda A, Vianello E, Furlan A, Bazzocchi M (2008) Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. Breast 17:623–630CrossRefPubMed Londero V, Zuiani C, Linda A, Vianello E, Furlan A, Bazzocchi M (2008) Lobular neoplasia: core needle breast biopsy underestimation of malignancy in relation to radiologic and pathologic features. Breast 17:623–630CrossRefPubMed
14.
Zurück zum Zitat Mahoney MC, Robinson-Smith TM, Shaughnessy EA (2006) Lobular neoplasia at 11-guage vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow up. AJR 187:949–954CrossRefPubMed Mahoney MC, Robinson-Smith TM, Shaughnessy EA (2006) Lobular neoplasia at 11-guage vacuum-assisted stereotactic biopsy: correlation with surgical excisional biopsy and mammographic follow up. AJR 187:949–954CrossRefPubMed
15.
Zurück zum Zitat Menon S, Porter G, Evans AJ, Ellis I, Elston CW, Hodi Z, Lee A (2008) The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch 452:473–479CrossRefPubMedPubMedCentral Menon S, Porter G, Evans AJ, Ellis I, Elston CW, Hodi Z, Lee A (2008) The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch 452:473–479CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB (2014) Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow up in a multidisciplinary setting. Cancer Med 3(3):492–499CrossRefPubMedPubMedCentral Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB (2014) Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow up in a multidisciplinary setting. Cancer Med 3(3):492–499CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Mulheron B, Gray RJ, Pockaj BA, Apsey H (2009) Is excisional biopsy indicated for patients with lobular neoplasia diagnosed on percutaneous core needle biopsy of the breast? Am J Surg 198:792–797CrossRefPubMed Mulheron B, Gray RJ, Pockaj BA, Apsey H (2009) Is excisional biopsy indicated for patients with lobular neoplasia diagnosed on percutaneous core needle biopsy of the breast? Am J Surg 198:792–797CrossRefPubMed
18.
Zurück zum Zitat Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E (2013) Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer 119:1073–1079CrossRefPubMed Murray MP, Luedtke C, Liberman L, Nehhozina T, Akram M, Brogi E (2013) Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer 119:1073–1079CrossRefPubMed
19.
Zurück zum Zitat Nagi CS, O’Donnell JE, Bleiweiss IJ, Jaffer SM (2008) Lobular neoplasia on core needle biopsy does not require excision. Cancer 112:2152–2158CrossRefPubMed Nagi CS, O’Donnell JE, Bleiweiss IJ, Jaffer SM (2008) Lobular neoplasia on core needle biopsy does not require excision. Cancer 112:2152–2158CrossRefPubMed
20.
Zurück zum Zitat Niell B, Specht M, Gerade B, Rafferty E (2012) Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR 199:929–935CrossRefPubMed Niell B, Specht M, Gerade B, Rafferty E (2012) Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR 199:929–935CrossRefPubMed
21.
Zurück zum Zitat Purdie CA, McLean D, Stormonth E, Macaskill EJ, McCullough JB, Edwards SL, Brown DC, Jordan LB (2010) Management of in situ lobular neoplasia detected on needle core biopsy of breast. J Clin Pathol 63:987–993CrossRefPubMed Purdie CA, McLean D, Stormonth E, Macaskill EJ, McCullough JB, Edwards SL, Brown DC, Jordan LB (2010) Management of in situ lobular neoplasia detected on needle core biopsy of breast. J Clin Pathol 63:987–993CrossRefPubMed
22.
Zurück zum Zitat Atkins KA, Cohen MA, Nicholson B, Rao S (2013) Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation. Radiology 269(2):340–347CrossRefPubMed Atkins KA, Cohen MA, Nicholson B, Rao S (2013) Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation. Radiology 269(2):340–347CrossRefPubMed
23.
Zurück zum Zitat Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH (2012) Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol 19:914–921CrossRefPubMed Rendi MH, Dintzis SM, Lehman CD, Calhoun KE, Allison KH (2012) Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol 19:914–921CrossRefPubMed
24.
Zurück zum Zitat Shah-Kahn MG, Geiger X, Reynolds C, Jakub J, DePeri ER, Glazebrook K (2012) Long term follow up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol 19:3131–3138CrossRef Shah-Kahn MG, Geiger X, Reynolds C, Jakub J, DePeri ER, Glazebrook K (2012) Long term follow up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol 19:3131–3138CrossRef
25.
Zurück zum Zitat Lewis JL, Lee DY, Tartter PI (2012) The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol 19:4124–4128CrossRefPubMed Lewis JL, Lee DY, Tartter PI (2012) The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol 19:4124–4128CrossRefPubMed
26.
Zurück zum Zitat Sohn VY, Arthurs ZM, Kim FS, Brown TA (2008) Lobular neoplasia: is surgical excision warranted? Am Surg 74(2):172–177PubMed Sohn VY, Arthurs ZM, Kim FS, Brown TA (2008) Lobular neoplasia: is surgical excision warranted? Am Surg 74(2):172–177PubMed
27.
Zurück zum Zitat Middleton LP, Palacios DM, Bryant BR et al (2000) Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24:1650–1656CrossRefPubMed Middleton LP, Palacios DM, Bryant BR et al (2000) Pleomorphic lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am J Surg Pathol 24:1650–1656CrossRefPubMed
28.
Zurück zum Zitat Brem R, Lechner M, Jackman R, Rapelyea J, Evans W et al (2008) Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR 190:637–641CrossRefPubMed Brem R, Lechner M, Jackman R, Rapelyea J, Evans W et al (2008) Lobular neoplasia at percutaneous breast biopsy: variables associated with carcinoma at surgical excision. AJR 190:637–641CrossRefPubMed
29.
Zurück zum Zitat Susnik B, Day D, Krueger J, Abeln E, Bowman T et al (2016) Surgical outcome of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer 16(6):507–513CrossRefPubMed Susnik B, Day D, Krueger J, Abeln E, Bowman T et al (2016) Surgical outcome of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases. Clin Breast Cancer 16(6):507–513CrossRefPubMed
31.
Zurück zum Zitat American Society of Breast Surgeons Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions, p. 3 American Society of Breast Surgeons Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions, p. 3
Metadaten
Titel
Observation versus excision of lobular neoplasia on core needle biopsy of the breast
verfasst von
Hank Schmidt
Brittany Arditi
Margaux Wooster
Christina Weltz
Laurie Margolies
Ira Bleiweiss
Elisa Port
Shabnam Jaffer
Publikationsdatum
03.01.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4629-2

Weitere Artikel der Ausgabe 3/2018

Breast Cancer Research and Treatment 3/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.